MA53177A - Apyrases solubilisées, méthodes et utilisation - Google Patents

Apyrases solubilisées, méthodes et utilisation

Info

Publication number
MA53177A
MA53177A MA053177A MA53177A MA53177A MA 53177 A MA53177 A MA 53177A MA 053177 A MA053177 A MA 053177A MA 53177 A MA53177 A MA 53177A MA 53177 A MA53177 A MA 53177A
Authority
MA
Morocco
Prior art keywords
apyrases
solubilized
methods
solubilized apyrases
Prior art date
Application number
MA053177A
Other languages
English (en)
Inventor
Agostino Cirillo
Hilmar Ebersbach
Boerje Haraldsson
Thomas Huber
Guido Junge
Regina Link
Max Warncke
Chao Zou
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA53177A publication Critical patent/MA53177A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01005—Apyrase (3.6.1.5), i.e. ATP diphosphohydrolase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
MA053177A 2018-07-18 2019-07-17 Apyrases solubilisées, méthodes et utilisation MA53177A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18184269 2018-07-18

Publications (1)

Publication Number Publication Date
MA53177A true MA53177A (fr) 2021-05-26

Family

ID=62985993

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053177A MA53177A (fr) 2018-07-18 2019-07-17 Apyrases solubilisées, méthodes et utilisation

Country Status (27)

Country Link
US (2) US12325870B2 (fr)
EP (1) EP3824079A1 (fr)
JP (2) JP7425784B2 (fr)
KR (1) KR102919646B1 (fr)
CN (6) CN119162148A (fr)
AR (1) AR115790A1 (fr)
AU (1) AU2019306821B2 (fr)
BR (1) BR112021000586A2 (fr)
CA (1) CA3103684A1 (fr)
CL (1) CL2021000129A1 (fr)
CO (1) CO2021000210A2 (fr)
CR (1) CR20210021A (fr)
CU (1) CU24746B1 (fr)
EA (1) EA202190057A1 (fr)
EC (1) ECSP21002804A (fr)
IL (1) IL280191A (fr)
JO (1) JOP20210008A1 (fr)
MA (1) MA53177A (fr)
MX (1) MX2021000542A (fr)
MY (1) MY203583A (fr)
PE (1) PE20210185A1 (fr)
PH (1) PH12021550122A1 (fr)
SG (1) SG11202011776RA (fr)
TW (1) TWI857965B (fr)
UY (1) UY38299A (fr)
WO (1) WO2020016804A1 (fr)
ZA (1) ZA202007187B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY38299A (es) * 2018-07-18 2020-02-28 Novartis Ag Apirasas solubilizadas, métodos y usos
EP4157131A4 (fr) * 2020-05-28 2024-10-02 Charm Sciences, Inc. Procédés et ensembles pour analyse d'échantillon
WO2024023745A1 (fr) 2022-07-29 2024-02-01 Novartis Ag Traitement d'une lésion organique aiguë à l'aide de cd39, de cd39 recombinant
KR20250044704A (ko) 2022-07-29 2025-04-01 노파르티스 아게 Cd39 변이체의 개선된 생산
WO2025080755A1 (fr) * 2023-10-13 2025-04-17 Nutrition & Biosciences USA 4, Inc. Procédés et compositions pour le vieillissement et la santé mitochondriale

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6447771B1 (en) 1999-03-19 2002-09-10 Hyseq, Inc. Methods and materials relating to novel CD39-like polypeptides
CA2345382A1 (fr) * 1998-10-16 2000-04-27 Immunex Corporation Inhibiteurs de l'activation et du recrutement plaquettaires
US20020002277A1 (en) * 1998-10-16 2002-01-03 Maliszewski Charles Richard Inhibitors of platelet activation and recruitment
US6867177B2 (en) 1999-08-13 2005-03-15 The Trustees Of Columbia University In The City Of New York CD39/ECTO-adpase as a treatment for thrombotic and ischemic disorders
US7247300B1 (en) 2002-11-07 2007-07-24 Apt Therapeutics, Inc. Therapeutic use of soluble CD39L3
EP1861498A4 (fr) 2005-03-17 2009-06-24 Ca Nat Research Council Vecteurs d'expression pour l'expression genetique transitoire et cellules mammaliennes les exprimant
WO2008002157A1 (fr) 2006-06-27 2008-01-03 Agresearch Limited Apyrases et utilisations correspondantes
CA2787016C (fr) * 2010-01-13 2018-01-23 Apt Therapeutics, Inc. Structure therapeutiques d'apyrase, agents de type apyrase et methodes de production
WO2011088231A1 (fr) 2010-01-13 2011-07-21 Apt Therapeutics, Inc. Traitement thérapeutique à l'apyrase des états pathologiques hémorragiques
JP6708548B2 (ja) 2013-12-20 2020-06-10 ノバルティス アーゲー 新規真核細胞および目的の生成物を組換え発現させるための方法
EP3083677B1 (fr) 2013-12-20 2019-08-28 Novartis AG Nouvelles cellules eucaryotes et procédés d'expression de manière recombinante d'un produit d'intérêt
UY38299A (es) 2018-07-18 2020-02-28 Novartis Ag Apirasas solubilizadas, métodos y usos

Also Published As

Publication number Publication date
JP7425784B2 (ja) 2024-01-31
CO2021000210A2 (es) 2021-01-18
MX2021000542A (es) 2021-03-29
CN112424346B (zh) 2024-08-06
US12325870B2 (en) 2025-06-10
CN119020321A (zh) 2024-11-26
CN119020320A (zh) 2024-11-26
CN112424346A (zh) 2021-02-26
AR115790A1 (es) 2021-02-24
CN119020318A (zh) 2024-11-26
KR20210035806A (ko) 2021-04-01
CU20210008A7 (es) 2021-08-06
CN119020319A (zh) 2024-11-26
EP3824079A1 (fr) 2021-05-26
TWI857965B (zh) 2024-10-11
US20250179447A1 (en) 2025-06-05
US20220356455A1 (en) 2022-11-10
MY203583A (en) 2024-07-05
ECSP21002804A (es) 2021-04-29
JP7853263B2 (ja) 2026-04-28
JOP20210008A1 (ar) 2021-01-12
EA202190057A1 (ru) 2021-08-24
SG11202011776RA (en) 2021-02-25
JP2021529550A (ja) 2021-11-04
KR102919646B1 (ko) 2026-01-29
PH12021550122A1 (en) 2021-09-27
PE20210185A1 (es) 2021-02-02
AU2019306821A1 (en) 2020-12-24
CR20210021A (es) 2021-03-23
TW202016299A (zh) 2020-05-01
IL280191A (en) 2021-03-01
BR112021000586A2 (pt) 2021-04-06
CA3103684A1 (fr) 2020-01-23
WO2020016804A1 (fr) 2020-01-23
UY38299A (es) 2020-02-28
CL2021000129A1 (es) 2021-08-20
AU2019306821B2 (en) 2022-09-29
CN119162148A (zh) 2024-12-20
ZA202007187B (en) 2022-06-29
CU24746B1 (es) 2025-04-04
JP2024023297A (ja) 2024-02-21

Similar Documents

Publication Publication Date Title
IL293061A (en) Collaborative networking systems, methods, and devices
IL272089B1 (en) Compounds, compositions and methods
EP3643726A4 (fr) Nanocorps anti-her2, séquence de codage et utilisation associée
EP3687093A4 (fr) Procédé, appareil, et dispositif de communication
EP3780786A4 (fr) Procédé et appareil de communication
EP3843739A4 (fr) Nouvelles méthodes
EP3672991A4 (fr) Molécules anti-cd137 et utilisation correspondante
EP3713364A4 (fr) Procédé et appareil de communication
EP3843738A4 (fr) Nouvelles méthodes
EP3637683C0 (fr) Procédés, fonction d'entité et système de gestion de session
EP3801527A4 (fr) Nouvelles méthodes
EP3633034A4 (fr) PROTÉINE Cas9 MODIFIÉE, ET APPLICATION ASSOCIÉE
EP4044630C0 (fr) Procédé, appareil et dispositif de communication
EP3611994A4 (fr) Procédé de planification semi-persistante, équipement utilisateur et dispositif de réseau
EP3616426C0 (fr) Configuration de la politique réseau
IL282178A (en) Products, uses & methods
EP3817422A4 (fr) Procédé et dispositif de communication
EP3771283A4 (fr) Procédé et appareil de communication
EP3863334A4 (fr) Procédé et appareil de communication
EP3886504C0 (fr) Procédé de communication d'informations, équipement utilisateur et dispositif de réseau
EP3582169A4 (fr) Appareil, système et procédé de présentation de marchandises
EP3993527C0 (fr) Procédés et appareils de communication
KR102528125B9 (ko) 정보 처리 방법, 장치 및 기기
EP4059305A4 (fr) Procédés et appareils de communication
EP3709751A4 (fr) Procédé d'accès aléatoire, équipement utilisateur et dispositif de réseau